131I-MIBG

RADIATION9 trials

Conditions

High Risk NeuroblastomaNeoplasmsNeuroblastomaNeuroectodermal TumorsNeuroendocrine Tumor Gastrointestinal, Hormone-SecretingNeuroendocrine Tumor, MalignantParagangliomaPhaeochromocytoma

Early Phase 1

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Active, not recruitingNCT03044977

David BushnellNeuroendocrine Tumor Gastrointestinal, Hormone-Secreting, Neuroendocrine Tumor, Malignant

Start: 2017-05-07End: 2027-12-31Target: 20Updated: 2023-08-16

Phase 1

Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

WithdrawnNCT01941849

University College, LondonParaganglioma, Phaeochromocytoma

Start: 2014-10-31End: 2015-12-31Updated: 2015-12-21

MIBG With Dinutuximab +/- Vorinostat

CompletedNCT03332667

New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma

Start: 2018-09-12End: 2024-02-23Updated: 2025-04-16

Phase 2

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

NCT00013806

National Center for Research Resources (NCRR)Neuroblastoma

Updated: 2005-06-24

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

CompletedNCT00253435

New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma

Start: 2005-09-01End: 2013-12-01Updated: 2026-04-28

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

CompletedNCT01413503

University of California, San FranciscoParaganglioma, Pheochromocytoma

Start: 1991-05-31End: 2009-05-31Updated: 2018-09-18

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

CompletedNCT02035137

New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma

Start: 2014-07-31End: 2021-02-26Updated: 2022-06-08

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

NCT03061656

Samsung Medical CenterHigh Risk Neuroblastoma

Start: 2009-01-01End: 2018-12-31Target: 40Updated: 2018-09-18

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

NCT03561259

Jubilant DraxImage Inc.Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Start: 2019-10-21End: 2025-04-30Target: 60Updated: 2023-02-16

Journal of Clinical Oncology2022-06-013 citations

Modulation of radiation biomarkers in a randomized phase II study of <sup>131</sup>I-MIBG with or without radiation sensitizers for relapsed or refractory neuroblastoma: A report from the NANT Consortium.

Journal of Clinical Oncology2022-06-01

Clinical and biologic predictors of response to MIBG therapy: A report from the new approaches to neuroblastoma therapy (NANT) consortium.

Journal of Clinical Oncology2022-06-01

Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma.

Journal of Clinical Oncology2021-05-201 citations

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

Journal of Clinical Oncology2020-05-204 citations

Modulation of radiation biomarkers in a randomized phase II study of <sup>131</sup>I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.

Journal of Clinical Oncology2020-05-20

Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

Journal of Hematology & Oncology2017-05-1646 citations

131I-MIBG

Sponsors

Conditions

Early Phase 1

Phase 1

Phase 2

Related Papers